R&D Investment in GBS-007 Commercial Manufacturing and Cost Reduction and in JRM-001
First written in FY2021. 2 of 3 entries say "Reframed", first in FY2022. Latest entry: FY2023.
Kidswell Bio moved to the "Worse" side of this theme in 2022.
The whole theme swung hardest in 2022: 1 of 8 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2023ReframedAnnual report
「The company plans to recognize ¥1,600.000 million in R&D expenses over the coming year. These R&D expenses mainly comprise temporary expenditures for development aimed at realizing SHED's growth strategy and measures to reduce the cost of goods sold for the ranibizumab biosimilar.」
The planned R&D expenses for the next year were updated from the previous ¥1,400 million to ¥1,600 million, with the uses of funds organized around SHED’s growth strategy and cost reduction for the ranibizumab biosimilar. - FY2022ReframedAnnual report
「The cash-flow outlook for the next year includes planned research and development expenses of ¥1,400 million. These R&D expenses will consist mainly of one-time expenditures for development aimed at realizing SHED’s growth strategy and cost-reduction measures for a ranibizumab biosimilar.」
The planned R&D expenses for the next year were updated from the previous plan of ¥1,800 million to ¥1,400 million, and the main uses of funds were reorganized from commercial manufacturing of GBS-007 and development costs for JRM-001 to SHED’s growth strategy and ranibizumab cost reduction. - FY2021First statedAnnual report
「The cash-flow outlook for the next year includes planned research and development expenses of ¥1,800 million. These R&D expenses will consist mainly of one-time and final expenditures for development toward commercial manufacturing of GBS-007 and cost-reduction measures. They also include development costs for JRM-001, which will represent a significant investment.」
The Company presented a plan to record ¥1,800 million in R&D expenses over the next year, identifying development toward commercial manufacturing and cost-reduction measures for GBS-007 and development costs for JRM-001 as the main uses of funds.